NEUNEUREN PHARMACEUTICALS LIMITEDMarket sensitive

2025 royalty income A$65m, profit after tax A$30m

Date and time
Announcement type
Financial Results

More from Health Care

More News

ARLCompany Update12 November 2026

Ardea Resources (ASX: ARL) Scandium Study Models US$510m NPV